Ensign Peak Advisors Inc Decreases Stock Holdings in argenx SE (NASDAQ:ARGX)

Ensign Peak Advisors Inc lessened its stake in argenx SE (NASDAQ:ARGX) by 3.7% in the 4th quarter, Holdings Channel.com reports. The fund owned 40,164 shares of the company’s stock after selling 1,540 shares during the quarter. Ensign Peak Advisors Inc’s holdings in argenx were worth $24,701,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. GeoWealth Management LLC increased its stake in shares of argenx by 56.3% during the fourth quarter. GeoWealth Management LLC now owns 50 shares of the company’s stock worth $31,000 after purchasing an additional 18 shares in the last quarter. Steward Partners Investment Advisory LLC raised its holdings in shares of argenx by 5.6% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 380 shares of the company’s stock valued at $234,000 after acquiring an additional 20 shares during the last quarter. SG Americas Securities LLC lifted its position in shares of argenx by 6.2% in the fourth quarter. SG Americas Securities LLC now owns 358 shares of the company’s stock valued at $220,000 after acquiring an additional 21 shares in the last quarter. Farther Finance Advisors LLC boosted its stake in shares of argenx by 38.2% in the fourth quarter. Farther Finance Advisors LLC now owns 76 shares of the company’s stock worth $47,000 after acquiring an additional 21 shares during the last quarter. Finally, Dynasty Wealth Management LLC raised its stake in argenx by 3.4% in the 4th quarter. Dynasty Wealth Management LLC now owns 677 shares of the company’s stock valued at $416,000 after purchasing an additional 22 shares during the last quarter. Hedge funds and other institutional investors own 60.32% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on ARGX shares. Sanford C. Bernstein raised shares of argenx from a “market perform” rating to an “outperform” rating in a report on Monday, March 17th. Robert W. Baird boosted their target price on argenx from $650.00 to $680.00 and gave the stock a “neutral” rating in a report on Tuesday, March 4th. Truist Financial reaffirmed a “buy” rating and issued a $700.00 price target (up previously from $660.00) on shares of argenx in a report on Tuesday, January 14th. Wells Fargo & Company upped their target price on argenx from $723.00 to $741.00 and gave the company an “overweight” rating in a report on Friday, February 28th. Finally, HC Wainwright reissued a “buy” rating and set a $720.00 price target on shares of argenx in a research report on Tuesday, April 8th. Three research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $697.94.

argenx Trading Down 3.4 %

ARGX stock opened at $549.65 on Friday. The business’s fifty day moving average price is $596.27 and its 200 day moving average price is $613.38. argenx SE has a 12-month low of $352.77 and a 12-month high of $678.21. The company has a market capitalization of $33.56 billion, a PE ratio of -624.60 and a beta of 0.57.

argenx (NASDAQ:ARGX) last issued its quarterly earnings results on Thursday, May 8th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.32 by $0.26. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The business had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $748.34 million. Research analysts predict that argenx SE will post 3.13 EPS for the current fiscal year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.